cas 90213-66-4|| where to buy 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

Nom du produit:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

Unité d'emballage	Stock disponible	Prix($)
CM103618-100g	in stock	ŴɅ
CM103618-500g	in stock	țțǊ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 90213-66-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:90213-66-4; Formule moléculaire:C6H3Cl2N3; Point de fusion:-; Code SMILES:ClC1=NC(Cl)=C2C=CNC2=N1; Densité:

: Numéro de catalogue:CM103618; Poids moléculaire:188.01; Point d'ébullition:; N° Mdl:MFCD08059278; Stockage:-20°C

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: Capivasertib; On November 16, FDA approved Capivasertib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer. Capivasertib is a highly selective inhibitor targeting three AKT subtypes (AKT1/2/3), which can block signals used by cancer cells for division and growth.